Alnylam Pharmaceuticals : and Collaborators to Present APOLLO Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting for Patients and Doctors
October 20, 2017 at 07:01 am EDT
Share
– Company to Host Conference Call on Thursday, November 2, 2017, at
12:30 pm ET to Discuss Results –
Alnylam
Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics
company, announced today that the results of the APOLLO Phase 3 study of
patisiran in hereditary ATTR (hATTR) amyloidosis patients with
polyneuropathy, as well as additional posters on patisiran and hATTR
amyloidosis, will be presented at the 1st European ATTR
Amyloidosis Meeting for Patients and Doctors being held November 2-3,
2017 in Paris, France.
Presentations include:
Patisiran, an investigational RNAi therapeutic for patients with
hereditary transthyretin-mediated (hATTR) amyloidosis with
polyneuropathy: Results from the Phase 3 APOLLO study Authors:
D Adams, A Gonzalez-Duarte, W O'Riordan, CC Yang, T Yamashita, A
Kristen, I Tournev, H Schmidt, T Coelho, JL Berk, KP Lin, PJ Dyck, P
Gandhi, M Sweetser, J Chen, J Gollob, O Suhr Presentation type:
Oral Date/time: November 2, 2017, 3:35 pm CET
Long-term, open-label clinical experience with patisiran, an
investigational RNAi therapeutic for patients with hereditary
transthyretin-mediated (hATTR) amyloidosis with polyneuropathy Authors:
JL Berk, D Adams, O Suhr, I Conceicao, M Waddington Cruz, H Schmidt, J
Buades, J Campistol, J Pouget, M Polydefkis, AM Partisano, M Sweetser,
J Chen, J Gollob, T Coelho Presentation type: Poster Date:
November 2-3, 2017
Reasons for Discontinuation of TTR Stabilizers and/or TTR Fibril
Disrupter: An Analysis of Baseline Demographics of Patients with hATTR
Amyloidosis in the Phase 3 APOLLO Study Authors: H Schmidt, W
O’Riordan, T Yamashita, JL Berk, I Tournev, M Mezei, V
Plante-Bordeneuve, Y Sekijima, OB Suhr, G Vita, AM Partisano, J
Gollob, D Adams Presentation type: Poster Date: November
2-3, 2017
Characteristics of patients with hereditary transthyretin-mediated
amyloidosis on the US liver transplant waiting list Authors:
D Brandman, SA Živković, W Irish, LM Gache, A McManus, J Gollob, AM
Partisano, S Agarwal Presentation type: Poster Date:
November 2-3, 2017
Alnylam management will discuss these results via conference call on
Thursday, November 2, 2017, at 12:30 p.m. ET. A slide presentation will
also be available on the Investors page of the Company’s website, www.alnylam.com,
to accompany the conference call. To access the call, please dial
877-312-7507 (domestic) or 631-813-4828 (international) five minutes
prior to the start time and refer to conference ID 2354344. A replay of
the call will be available beginning at 3:30 p.m. ET on the day of the
call. To access the replay, please dial (855) 859-2056 (domestic) or
(404) 537-3406 (international), and refer to conference ID 2354344.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference
(RNAi) into a whole new class of innovative medicines with the potential
to transform the lives of people afflicted with rare genetic,
cardio-metabolic, and hepatic infectious diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
severe and debilitating diseases. Founded in 2002, Alnylam is delivering
on a bold vision to turn scientific possibility into reality, with a
robust discovery platform and deep pipeline of investigational
medicines, including four product candidates that are in late-stage
development. Looking forward, Alnylam will continue to execute on its
"Alnylam 2020" strategy of building a multi-product, commercial-stage
biopharmaceutical company with a sustainable pipeline of RNAi-based
medicines to address the needs of patients who have limited or
inadequate treatment options. Alnylam employs over 600 people in the
U.S. and Europe and is headquartered in Cambridge, MA. For more
information about our people, science and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171020005202/en/
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.